ProMIS Neurosciences Launches Phase 1b Trial for Alzheimer’s

ProMIS Neurosciences ( (PMN) ) has issued an announcement.

ProMIS Neurosciences announced the initiation of its Phase 1b clinical trial for PMN310, a therapeutic candidate aimed at treating Alzheimer’s disease by selectively targeting toxic amyloid-beta oligomers. The trial will assess safety, tolerability, and efficacy over 12 months in 100 patients, with the potential for PMN310 to offer a differentiated product profile by reducing the risk of amyloid-related imaging abnormalities. The company aims to address the unmet needs in Alzheimer’s treatment through this trial, which collaborates with leading U.S. treatment centers.

More about ProMIS Neurosciences

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, including Alzheimer’s disease, amyotrophic lateral sclerosis, and multiple system atrophy. The company utilizes a proprietary discovery platform to design antibody therapeutics targeting toxic misfolded proteins, with PMN310 as its lead product candidate for Alzheimer’s disease.

YTD Price Performance: 6.25%

Average Trading Volume: 70,551

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $33.34M

Find detailed analytics on PMN stock on TipRanks’ Stock Analysis page.